That is true. I have been speaking to a lot of funds that are large enough to be able to afford to have a biotech analysts, yet few do. When I get to talk to those that do have one, the quality of conversation is on another level - instead of talking about short term catalysts of the SP, I get into the nitty-gritty of our development and commercialisation strategy. These investors really get what we are trying to do and can see the value, not just can how they make a quick buck to boost their quarterly numbers.
RAC - Charts & Price Action, page-333
- There are more pages in this discussion • 20,623 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.075(5.32%) |
Mkt cap ! $239.5M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.49 | $1.43 | $206.8K | 142.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.50 | 5084 | 2 |
View Market Depth
| Last trade - 13.12pm 13/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.49 |
Change
0.075 ( 7.63 %) |
||||
| Open | High | Low | Volume | ||
| $1.45 | $1.49 | $1.44 | 10984 | ||
| Last updated 13.53pm 13/05/2024 ? | |||||
| RAC (ASX) Chart |